Innate Pharma (Nasdaq: IPHA) files 2025 AMF URD and SEC Form 20-F
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Innate Pharma S.A. has filed its 2025 Universal Registration Document with the French market authority AMF and its 2025 Form 20-F annual report with the U.S. SEC, both covering the year ended December 31, 2025. These filings include the annual financial report, management report, corporate governance report, and statutory auditors’ report.
Innate Pharma is a clinical-stage biotechnology company focused on cancer immunotherapies, developing next-generation antibody-based drugs such as IPH4502, lacutamab and monalizumab, in collaboration with partners including AstraZeneca and Sanofi.
Positive
- None.
Negative
- None.
Key Terms
Universal Registration Document, Form 20-F annual report, clinical-stage biotechnology company, immunotherapies for cancer, +2 more
6 terms
Universal Registration Document regulatory
"announced the filing of its 2025 Universal Registration Document"
A universal registration document is a single, comprehensive filing that collects a publicly traded company's key disclosures — such as business description, financial statements, risk factors, governance and legal information — into one place for regulators and investors. Think of it as a detailed owner’s manual and scorecard combined: it saves time when the company issues new shares or bonds and helps investors compare, check risks, and make informed decisions without hunting through many separate reports.
Form 20-F annual report regulatory
"the filing of its Form 20-F annual report for the year ending December 31, 2025"
clinical-stage biotechnology company financial
"Innate Pharma S.A. is a global, clinical-stage biotechnology company"
immunotherapies for cancer medical
"developing immunotherapies for cancer patients"
Nectin-4 ADC medical
"IPH4502, a differentiated Nectin-4 ADC developed in solid tumors"
anti-NKG2A antibody medical
"monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca"
FAQ
What did Innate Pharma (IPHA) announce in this Form 6-K?
Innate Pharma announced it filed its 2025 Universal Registration Document with the AMF and its 2025 Form 20-F annual report with the SEC, covering the year ended December 31, 2025, consolidating financial, management and governance information.
Where can investors access Innate Pharma’s 2025 Universal Registration Document and Form 20-F?
The 2025 Universal Registration Document can be downloaded from Innate Pharma’s website and the AMF website. The 2025 Form 20-F annual report is available on Innate Pharma’s website and on the U.S. SEC’s website for public access.
What information is included in Innate Pharma’s 2025 Universal Registration Document?
The Universal Registration Document incorporates the annual financial report, the annual management report, the corporate governance report required under French law, and the statutory auditors’ report, providing a comprehensive overview of Innate Pharma’s 2025 operations and governance.
What type of company is Innate Pharma (IPHA) and what does it develop?
Innate Pharma is a global, clinical-stage biotechnology company developing cancer immunotherapies. It focuses on innovative, next-generation antibody therapeutics designed to harness the immune system to treat tumors with high unmet medical need across various solid and blood cancers.
Which key drug candidates are highlighted in Innate Pharma’s pipeline?
Innate Pharma highlights IPH4502, a Nectin-4 antibody-drug conjugate for solid tumors, lacutamab, an anti-KIR3DL2 antibody for cutaneous and peripheral T-cell lymphomas, and monalizumab, an anti-NKG2A antibody developed with AstraZeneca in non-small cell lung cancer.
Who are Innate Pharma’s major collaboration partners mentioned in the filing?
Innate Pharma reports collaborations with leading biopharmaceutical companies Sanofi and AstraZeneca, as well as academic and research institutions. These partnerships support the development and clinical testing of its immuno-oncology antibody programs across multiple cancer indications.